Invivyd is on a mission to rapidly and perpetually deliver antibody-based therapies that protect vulnerable people from the devastating consequences of circulating viral threats, beginning with SARS-CoV-2.

By pairing state-of-the-art viral surveillance and predictive modeling with advanced antibody engineering techniques, we are committed to developing a robust pipeline of product candidates which could be used in prevention or treatment of serious viral diseases, starting with COVID-19 and expanding into influenza and other high-need indications.


Leadership team

Invivyd’s leadership team is composed of seasoned executives with decades of combined experience developing and commercializing novel medicines for infectious diseases. Our leadership team includes individuals with extensive experience delivering vaccines that have helped protect people around the globe from serious viral threats, as well as leaders who have helped pioneer the development of monoclonal antibodies for use in the prevention and treatment of COVID-19.

Jeremy Gowler Chief Operating & Commercial Officer

Interim Chief Executive Officer

Robert Allen, Ph.D. Chief Scientific Officer

Chief Scientific Officer

Jill Andersen, J.D. Chief Legal Officer & Corporate Secretary

Chief Legal Officer & Corporate Secretary

William Duke, M.B.A. Chief Financial Officer

Chief Financial Officer

Chief Human Resources Officer

Stacy Price, M.S. Chief Technology & Manufacturing Officer

Chief Technology & Manufacturing Officer

Heidi Spurling, M.S. Vice President of Strategy and Operations & Chief of Staff

Vice President of Strategy and Operations & Chief of Staff


Board of directors

Partner, Population Health Partners

Portfolio Manager and Senior Investment Analyst, UBS Global Asset Management

Chairperson of the Board | Founder and Chief Investment Officer, M28 Capital Management L.P.

Former President, Johnson & Johnson Development Corporation (JJDC)

Partner, Polaris Partners

Executive Chair and Co-founder, Population Health Partners

Senior Vice President, Alnylam Pharmaceuticals, Inc.

President, MSW Consulting, Inc.



To achieve our mission, we have entered into a number of strategic partnerships and continue to evaluate potentially synergistic partnering opportunities, such as commercial partnerships that would help ensure that our portfolio of product candidates are available to as many vulnerable people as possible. In addition, we continue to evaluate therapeutic candidates for infectious diseases with high unmet medical need through in-licensing opportunities that may leverage our team’s expertise and capabilities.

Please contact us to explore partnering opportunities
Happy professional woman shaking hands with an Invivyd employee she is in partnership with Happy professional woman shaking hands with an Invivyd employee she is in partnership with